Search Results 981-990 of 14765 for anti-TNF drugs

1. Evaluation of CRS-207 With Pembrolizumab in Previously Treated MPM - Mayo Clinic

   The purpose of this study is to evaluate whether CRS-207 with pembrolizumab is safe and effective in adults with MPM who have failed prior anti-cancer therapy.

2. Nitrofurazone (Topical Route) Precautions - Mayo Clinic

   Precautions. Drug information provided by: Merative, Micromedex®. If your burn or skin infection does not improve, or if it becomes worse, check with your ...

3. Sulfacetamide And Prednisolone (Ophthalmic Route) Precautions - Mayo Clinic

   Precautions. Drug information provided by: Merative, Micromedex®. Your eye doctor will want to examine your eyes at regular visits to make sure this ...

4. A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria - Mayo Clinic

   (e.g., infliximab, adalimumab), and eosinophil-depleting drugs (e.g., benralizumab, pramipexole); (ii) routine (daily or every other day during 5 or more ...

5. Technetium Tc 99m Carbon (Inhalation Route) Side Effects - Mayo Clinic

   Side Effects. Drug information provided by: Merative, Micromedex®. Along with its needed effects, a medicine may cause some unwanted effects. Although not ...

6. Dorzolamide And Timolol (Ophthalmic Route) Precautions - Mayo Clinic

   Before you have any kind of surgery, dental treatment, or emergency treatment, tell the medical doctor or dentist in charge that you are using this medicine.

7. Tedizolid (Intravenous Route) Side Effects - Mayo Clinic

   Side Effects. Drug information provided by: Merative, Micromedex®. Along with its needed effects, a medicine may cause some unwanted effects. Although not ...

8. Intensity-Modulated Radiation Therapy and Paclitaxel with or without Pazopanib Hydrochloride in Treating Patients with Anaplastic Thyroid Cancer - Mayo Clinic

   Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.

9. A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients with Moderately to Severely Active Crohn's Disease (UNITI-2) - Mayo Clinic

   Patients who have received infliximab, adalimumab or certolizumab pegol ≤ 8 weeks before the first administration of study drug; Patients with certain ...

10. A Study to Assess Effectiveness and Safety of SER‑287 in Adults With Active Mild-to-Moderate Ulcerative Colitis - Mayo Clinic

    Drugs & Supplements A-Z · Health Books · Healthy ... By condition, treatment or drug name. Search tips. A ... anti-TNFα, anti-integrin or tofacitinib. If ...